MDGL · Madrigal Pharmaceuticals, Inc.
$434.24
-4.21% last session
End-of-day data · close of 2026-10-23
Market cap
$10B
Enterprise value
$10B
Trailing P/E
—
Forward P/E
45.1
Dividend yield
0.0%
Beta
-1.05
Avg volume
0M
Employees
1K
Daily Change %
-4.21%
5 Days Change
0.80%
10 Days Change
0.27%
30 Days Change
-11.63%
60 Days Change
-11.45%
Month to Day Change
-9.28%
Year to Day Change
-22.15%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MDGL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-23
Latest call per bank · past 12 months
Citigroup
Buy$725
+67.0% vs priceBarclays
Overweight$962
+121.5% vs priceWells Fargo
Overweight$685
+57.7% vs priceBank of America
Neutral$542
+24.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Citigroup | Initiates | Buy | $0.00 → $725 |
| 2026-08-04 | Wolfe Research | Upgrade | Peer Perform → Outperform | $0.00 → $605 |
| 2026-08-03 | Barclays | Maintains | Overweight | $964 → $962 |
| 2026-07-29 | Canaccord Genuity | Maintains | Buy | $578 → $587 |
| 2026-07-27 | Wells Fargo | Initiates | Overweight | $0.00 → $685 |
| 2026-06-11 | Bank of America | Maintains | Neutral | $550 → $542 |
| 2026-05-13 | Truist Securities | Maintains | Buy | $640 → $709 |
| 2026-05-07 | Canaccord Genuity | Maintains | Buy | $587 → $578 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 28 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 14.4% below the 50-day MA ($507.56).
- bearish: Price vs 200-day MA: Trading 13.5% below the 200-day MA ($501.99).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-1.79) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($412.35).
MDGL Price Chart
Loading chart for MDGL…
Fundamentals
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.